Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset

被引：7

作者：

de Wit, Emmie ^{[1
]}

Feldmann, Friederike ^{[2
]}

Horne, Eva ^{[1
]}

Okumur, Atsushi ^{[3
]}

Cameroni, Elisabetta ^{[4
]}

Haddock, Elaine ^{[1
]}

Saturday, Greg ^{[2
]}

Scott, Dana ^{[2
]}

Gopal, Robin ^{[5
]}

Zambone, Maria ^{[5
]}

Corti, Davide ^{[4
]}

Feldmann, Heinz ^{[1
]}

机构：

[1] NIAID, Lab Virol, NIH, Hamilton, MT USA

[2] NIAID, Rocky Mt Vet Branch, NIH, Hamilton, MT USA

[3] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY USA

[4] Humabs BioMed SA, CH-6500 Humabs BioMed SA, Switzerland

[5] Publ Hlth England, Natl Infect Serv, London NW9 5EQ, England

来源：

ANTIVIRAL RESEARCH | 2019年 / 163卷

关键词：

MERS-CoV; Treatment; Prophylaxis; Neutralizing monoclonal antibody; LCA60; Common marmoset; POSTEXPOSURE EFFICACY; NEUTRALIZING ANTIBODY; MOUSE MODEL; INFECTION;

D O I：

10.1016/j.antiviral.2019.01.016

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.

引用

收藏

页码：70 / 74

页数：5

相关论文

共 50 条

[31] Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV [J].

Sheahan, Timothy P. ;

Sims, Amy C. ;

Leist, Sarah R. ;

Schafer, Alexandra ;

Won, John ;

Brown, Ariane J. ;

Montgomery, Stephanie A. ;

Hogg, Alison ;

Babusis, Darius ;

Clarke, Michael O. ;

Spahn, Jamie E. ;

Bauer, Laura ;

Sellers, Scott ;

Porter, Danielle ;

Feng, Joy Y. ;

Cihlar, Tomas ;

Jordan, Robert ;

Denison, Mark R. ;

Baric, Ralph S. .

NATURE COMMUNICATIONS, 2020, 11 (01)

[32] T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV [J].

Liu, William J. ;

Zhao, Min ;

Liu, Kefang ;

Xu, Kun ;

Wong, Gary ;

Tan, Wenjie ;

Gao, George F. .

ANTIVIRAL RESEARCH, 2017, 137 :82-92

[33] Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection [J].

Raj, V. Stalin ;

Okba, Nisreen M. A. ;

Gutierrez-Alvarez, Javier ;

Drabek, Dubravka ;

van Dieren, Brenda ;

Widagdo, W. ;

Lamers, Mart M. ;

Widjaja, Ivy ;

Fernandez-Delgado, Raul ;

Sola, Isabel ;

Bensaid, Albert ;

Koopmans, Marion P. ;

Segales, Joaquim ;

Osterhaus, Albert D. M. E. ;

Bosch, Berend Jan ;

Enjuanes, Luis ;

Haagmans, Bart L. .

SCIENCE ADVANCES, 2018, 4 (08)

[34] Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction [J].

Omrani, Ali S. ;

Al-Tawfiq, Jaffar A. ;

Memish, Ziad A. .

PATHOGENS AND GLOBAL HEALTH, 2015, 109 (08) :354-362

[35] Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein [J].

Haverkamp, Ann-Kathrin ;

Bosch, Berend J. ;

Spitzbarth, Ingo ;

Lehmbecker, Annika ;

Te, Nigeer ;

Bensaid, Albert ;

Segales, Joaquim ;

Baumgaertner, Wolfgang .

VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2019, 218

[36] Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex [J].

Park, Byoung Kwon ;

Maharjan, Sony ;

Lee, Su In ;

Kim, Jinsoo ;

Bae, Joon-Yong ;

Park, Man-Seong ;

Kwon, Hyung-Joo .

BMB REPORTS, 2019, 52 (06) :397-402

[37] Bioinformatics analysis on potential anti-viral targets against spike protein of MERS-CoV Subtitle: Potential epitopes in MERS-CoV S Protein [J].

Li, Yan-Hua ;

Gao, Hainv ;

Xiao, Yunfeng ;

Weng, Tianhao ;

Yu, Dongshan ;

Hu, Chenyu ;

Yao, Hang-Ping ;

Li, Lan-Juan .

2018 NINTH INTERNATIONAL CONFERENCE ON INFORMATION TECHNOLOGY IN MEDICINE AND EDUCATION (ITME 2018), 2018, :67-71

[38] Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection [J].

Wang, Yufei ;

Tai, Wanbo ;

Yang, Jie ;

Zhao, Guangyu ;

Sun, Shihui ;

Tseng, Chien-Te K. ;

Jiang, Shibo ;

Zhou, Yusen ;

Du, Lanying ;

Gao, Jimin .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (07) :1615-1624

[39] Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China [J].

Wang, Wenling ;

Wang, Huijuan ;

Deng, Yao ;

Song, Tie ;

Lan, Jiaming ;

Wu, Guizhen ;

Ke, Changwen ;

Tan, Wenjie .

EMERGING MICROBES & INFECTIONS, 2016, 5

[40] Utilizing sinapic acid as an inhibitory antiviral agent against MERS-CoV PLpro [J].

Shahid, Mudassar ;

Alaofi, Ahmed L. ;

Ansari, Mushtaq Ahmad ;

Ahmad, Sheikh Fayaz ;

Alsuwayeh, Saleh ;

Taha, Ehab ;

Raish, Mohammad .

SAUDI PHARMACEUTICAL JOURNAL, 2024, 32 (04)

← 1 2 3 4 5 →